Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

1. Corvus released positive Phase 1 trial data for soquelitinib, showing efficacy. 2. Cohort 3 demonstrated earlier and deeper efficacy compared to lower dose cohorts. 3. Soquelitinib was well tolerated with minimal adverse effects reported. 4. Company plans to initiate Phase 2 trial and extension cohort data soon. 5. Corvus has sufficient funding until late 2026 for ongoing operations.